KPV, 10mg

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH, residues 11-13). Published research has investigated KPV in a variety of experimental signaling and inflammatory pathway models, where it has demonstrated melanocortin receptor-independent activity distinct from its parent peptide.

Molecular Signaling & Transport Mechanisms

Experimental findings indicate that KPV is transported intracellularly through the PepT1 oligopeptide transporter, exhibiting measurable affinity in intestinal epithelial cell models. In vitro studies have reported intracellular accumulation and modulation of NFκB-associated signaling pathways through interference with p65RelA/importin-α3 interactions, resulting in altered nuclear translocation dynamics.

Additional published investigations have evaluated KPV’s influence on MAPK signaling cascades, including ERK1/2, JNK, and p38 pathways in epithelial cell systems. Observed effects occurred independently of classical melanocortin receptor activation and were associated with altered inflammatory signaling marker expression in laboratory environments.

Experimental Gastrointestinal Models

KPV has been evaluated in multiple murine gastrointestinal inflammation models, including DSS and TNBS protocols commonly utilized in experimental intestinal research. Published observations reported measurable modulation of:

• Colonic myeloperoxidase activity
• Cytokine-associated signaling markers
• Epithelial integrity parameters
• Histological inflammatory cell infiltration
• Colon morphology metrics

Research has also identified increased PepT1 expression in inflamed epithelial and immune cell populations, suggesting a potential role for transporter-mediated peptide uptake under inflammatory experimental conditions.

Airway & Epithelial Cell Research

In bronchial epithelial cell models, KPV has been investigated for effects on TNFα-associated signaling activity. Published in vitro findings have reported modulation of:

• NFκB reporter activity
• IL-8 transcription
• MMP-9 gelatinolytic activity
• Eotaxin-associated signaling markers

These investigations continue to contribute to broader experimental understanding of epithelial inflammatory signaling pathways and peptide-transporter interactions.

Immune Signaling Studies

Functional PepT1 expression has been identified in several immune cell populations, including Jurkat T-cell models and intestinal immune tissues. Experimental studies have reported that nanomolar KPV exposure influenced IκBα-associated signaling dynamics and cytokine transcriptional activity following TNFα stimulation.

Inflammatory conditions have additionally been associated with increased PepT1 expression in macrophage and peripheral immune cell populations, supporting ongoing interest in transporter-mediated peptide delivery systems for research applications.

Dermatological Research Models

KPV has also been evaluated in experimental dermatological signaling studies. Unlike α-MSH, KPV does not significantly activate MC1R-associated melanogenesis pathways, allowing investigation of inflammatory signaling mechanisms without substantial pigmentation-related receptor activation.

Related stereoisomer analogs, including KdPT (Lys-D-Pro-Thr), have demonstrated increased proteolytic stability in laboratory analyses. Published sebocyte studies have further examined cytokine-signaling modulation in experimental skin cell systems.

Structure–Activity Relationships

Research investigating α-MSH truncation fragments has identified KPV as the minimal sequence retaining measurable anti-inflammatory signaling activity in several experimental models. Additional structure-activity studies evaluating D-amino acid substitutions (KdPV, KPdV, dKPV) reported preserved pathway activity alongside enhanced resistance to proteolytic degradation.

Chemical modifications such as glycoalkylation have also been explored to evaluate stability and structure-dependent bioactivity characteristics in peptide research systems.

KPV is not approved by the U.S. Food and Drug Administration for human use, and its safety, efficacy, and pharmacological profile have not been established in approved FDA clinical trials. It is not intended to diagnose, treat, cure, or prevent any disease.